Antidote closed a $23.2M funding round led by LBO France.

Antidote, a London, UK-based , announced the close of a $23.2M funding round.

The money was raised from investors led by LBO France with contributions from existing investors Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures.

Sebastien Woynar and Franck Noiret of LBO France will join the Antidote Board as a director and an observer, respectively.

The proceeds of the funding will be used to expand its digital patient engagement programs and clinical trial recruitment services.

Antidote, founded in 2010 by Eithan Ephrati, Jessica Mann and Pablo Graiver and led by Laurent Schockmel, CEO, is a digital health company providing a clinical trial matching service for patients distributed through a network of hundreds of patient advocacy groups, with the aim to offer precision patient recruitment for the life sciences industry as well.

The company uses precision recruitment to match the right patients with the right trials, striking the right balance between technology and human touch to deliver high-quality patient engagement. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK.